Women's Oncology Program - WON

妇女肿瘤学(韩元)--项目摘要/摘要 妇女肿瘤学计划(Won)旨在刺激高质量的基础、翻译和临床 通过合作、项目互动、信息共享和 招聘教师，并将研究成果转化为尖端诊断和治疗 癌症。妇女肿瘤学项目的负责人包括玛格丽特·A·舒普尼克，博士， 医学和生理学，分子内分泌学和雌激素受体作用方面的专家； 莫德西特。医学博士，妇产科教授，妇科肿瘤临床试验专家；以及 乔埃伦·M·斯奇尔克劳特，博士，公共卫生科学公共卫生硕士教授，遗传学和 女性癌症的流行病学，特别是乳腺癌和卵巢癌。韩元代表着各种各样的 拥有来自10个不同基础科学和临床的25名成员的智力、技术和临床专业知识 医学院和工程及应用科学学院的系，以及3名助理 会员。癌症中心对教师招聘和保留的支持，信息交流的论坛等 作为癌症中心研讨会系列、妇女肿瘤学月度研究会议和项目务虚会， 癌症中心试点研究基金，以及对我们共享资源的支持使 我们的研究项目取得了成功，这些项目已经变得越来越专注于癌症，并具有互动性。高潮 由此产生的科学的质量导致了许多高影响力的出版物，包括22%的国际 过去5年的方案出版物和18%的方案内出版物。目前的资金超过450万美元， 包括200万美元的NCI资金，对于乳房患者(17.5%)和卵巢患者来说，患者的收益是强劲的 (45.8%)2015年的癌症。在美国，每年有超过30万名新诊断的癌症患者，它 仍然是开发抗拒当前治疗途径、方法的癌症新疗法的关键 用于早期检测和预测反应的指标，以及评估风险和预防乳腺癌和 妇科癌症。Won计划制定了明确的目标和跨学科的小组 研究人员致力于解决女性癌症的这些关键问题。目的1：研究血管紧张素转换酶 女性癌症的治疗耐药及寻找预后指标和新分子 目标。目标2：了解代谢失调和肥胖是如何导致女性 癌症和确定潜在的新的治疗靶点。目标3.确定行为、荷尔蒙和 提高妇女癌症的遗传风险，并改进对这些癌症的检测方法。每个目标 包括跨越所有女性癌症的基础、转化和临床研究和试验。

WOMEN'S ONCOLOGY (WON) – PROJECT SUMMARY/ABSTRACT The Women's Oncology Program (WON) aims to stimulate high quality basic, translational, and clinical research and trials in women's cancers through collaborations, program interactions, information sharing, and faculty recruitment, and to translate the research findings into cutting edge diagnostics and treatments for cancer. Leaders of the Women's Oncology program include Margaret A. Shupnik, PhD, Professor of Medicine and Physiology, an expert in molecular endocrinology and estrogen receptor action; Susan C. Modesitt. MD, Professor of Obstetrics and Gynecology, an expert in gynecology-oncology clinical trials; and Joellen M. Schildkraut, PhD, MPH Professor of Public Health Sciences, an expert in the genetics and epidemiology of women's cancers, particularly breast and ovarian cancer. WON represents a wide variety of intellectual, technical, and clinical expertise with 25 members from 10 different basic science and clinical departments in the School of Medicine and School of Engineering and Applied Science, and 3 associate members. Cancer Center support for faculty recruitment and retention, forums for information exchange such as the Cancer Center Seminar Series, Women's Oncology monthly research meetings and Program Retreat, Cancer Center pilot research funds, and support for and from our Shared Resources have enabled the success of our research programs, which have become increasingly cancer-focused and interactive. The high quality of the resulting science resulted in numerous high impact publications, including 22% inter- programmatic and 18% intra-programmatic publications over the past 5 years. Current funding is over $4.5M, including $2M in NCI funding, and patient accrual was robust for patients with Breast (17.5%) and Ovarian (45.8%) cancers in 2015. With over 300,000 new diagnoses of these cancers yearly in the United States, it remains essential to develop new treatments for cancers resistant to current therapeutic approaches, methods for early detection and prognostic indicators for responses, and methods to assess risk and prevent breast and gynecological cancers. The WON program has developed specific aims and transdisciplinary groups of investigators to tackle these critical issues in women's cancers. Aim 1: To investigate pathways of therapeutic resistance in women's cancers and identify prognostic indicators and new molecular targets. Aim 2: To understand how dysregulation of metabolism and obesity contribute to women's cancers and identify potential new therapeutic targets. Aim 3. To identify behavioral, hormonal and genetic risks for women's cancers, and improve detection methods for these cancers. Each aim includes basic, translational and clinical research and trials that cut across all women's cancers.